Ophthalmologists must take measures to avoid misdiagnosing age-related macular degeneration and consider mimics of the ...

Although AI shows significant promise in diagnosing and managing age-related macular degeneration, its efficacy is reduced by ...

Key Takeaways Teva Pharmaceutical Industries and partner Alvotech said the Food and Drug Administration agreed to review ...

Signs and symptoms of age-related macular degeneration (AMD) are important to spot to prevent further deterioration of sight.

Here's what macular degeneration is, what causes it and how you can expect it to be treated if it affects you or a loved one.

Premorbid allergic diseases are linked with the development of age-related macular degeneration (AMD), however, the risk of allergic diseases among patients with AMD is largely unknown.To evaluate the ...

Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two ...

Age-related macular degeneration (AMD) is a progressive eye condition that primarily affects people over the age of 50. AMD is a leading cause of vision loss in people over 50.

Macular degeneration, also known as age-related macular degeneration or AMD, is an incurable eye disease that damages the middle part of the retina that's known as the macula, "which is ...

COAST Phase 3 trial evaluates superiority and safety of sozinibercept combined with aflibercept in wet AMDCompany confirms topline results for ...

So far, five biosimilars that reference Eylea 2 mg have been approved by the FDA. Alvotech/Teva expect to regulatory approval for its biosimilar to be completed in the fourth quarter of 2025.

Telomir Pharmaceuticals (NASDAQ: TELO) announced positive preclinical results demonstrating its lead compound, Telomir-1, significantly reduced react ...